Tivozanib Shows Benefits in Long-Term Survival for Relapsed/Refractory Renal Cell Carcinoma
In a post-hoc analysis, tivozanib (Fotivda; AVEO Oncology) showed a consistent safety profile and long-term survival for patients with relapsed/refractory (R/R) advanced renal cell carcinoma (RCC) who were alive and progression-free at 12 months, …